IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re:

Application of:

Hiroyuki ABURATANI et al.

Serial No.:

To Be Assigned

International

Appl. No.:

PCT/JP2004/011650

Filed:

August 6, 2004

For:

GENE OVEREXPRESSED IN CANCER

Mail Stop: PCT

Commissioner for Patents

February 8, 2006

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449 (2 pages) for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the foreign and non-patent references, which were cited in the International Search Report in the above-identified international application of which this application is a national phase filing, are enclosed herewith, along with a copy of the International Search Report.

If any fees are due at this time, the Commissioner is authorization to charge such fee to Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

Bv:

Morey B. Wildes

Reg. No. 36/968

DAVIDSON, DAVIDSON & KAPPEL, LLC 485 Seventh Avenue, 14th Floor New York, NY 10018 (212) 736-1940

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

′

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	te for form 1449A	VPTO		Complete if Known		
				Application Number	To Be Assigned (2,6) (3, 7)	
INFO	DRMATIC	ON DIS	CLOSURE	Filing Date	Herewith 1200 4	
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Hiroyuki ABURATANI, et al.	
				Art Unit	Not Yet Known	
	(Use as man	y sheets as	necessary)	Examiner Name	Not Yet Known	
Sheet	1	of	2	Attorney Docket Number	392.1004	

U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
Initials *	Cite No.1	Number - Kind Code ² (if known)	MM-DD-YYYY	Once Document			
/M.N./		US- 2003/0003538 A1	01-02-2003	Dietrich R.S., et al.			
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
	Î	US-					
		US-					
		US-					
		US-					
		US-					
		US-					
	1	US-					
		US-					
		US-					
		US-					
		US-					
		US-					

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
		Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)					
/M.N./		WO 02/046415 A2	06-13-2002	Incyte Genomics, Inc.			
/M:M:/		WO 03/029424 A2	04-10-2003	Curagen Corp.			
/M.N./		WO 04/040000 A2	05-13-2004	Primal Inc.			
·-							

Examiner	/Meera Natarajan/	Date Considered	/Meera Natarajan/
Signature	/wccra rvatarajan/	Considered	,

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO					Complete if Known		
	W.FOD.		D 10	OL COURT	Application Number	To Be Assigned (a) A 7	
	_	_	_	CLOSURE	Filing Date	Herewith 20050 6	
	STATE	MENT B	Y AI	PPLICANT	First Named Inventor	Hiroyuki ABURATANI, et al.	
					Art Unit	Not Yet Known	
(Use as many sheets as necessary)					Examiner Name	Not Yet Known	
abla	Sheet 2		of	2	Attorney Docket Number	392.1004	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
/M.N./		SCHEURLE, et al., Cancer gene discovery using digital differential display, Cancer Research, August 1, 2000, Vol. 60 (15), pp. 4037-4043				
/M.N./		Matthias, P.A. EBERT, et al., Expression of Metallothionein II in Intestinal Metaplasia, Dysplasia, and Gastric Cancer, Cancer Research, April 1, 2000, Vol. 60, pp. 1995-2001				
/M.N./		XU, et al., Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver, Proc. Natl. Acad. Sci. USA, December 18, 2001, Vol. 98 (26), pp. 15089-94				
,						
-			ļ			

Examiner	/Meera Natarajan/	Date	11/10/2008
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.